Fehminaz TEMEL, Dilek ALTUN, Burak ÖZTOP, Şeyda Kayhan ÖMEROĞLU

Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19

Background/aim: Due to the importance of early outpatient treatment to prevent hospitalization and disease progression, we examined the effects of hydroxychloroquine and favipiravir, which were initiated in early period, on the clinical course of COVID-19 outpatients. Materials and methods: Data of confirmed COVID-19 outpatients over a 4-month period were analyzed retrospectively. Public Health Management System (HSYS) was used for the case-based follow-up. Patients on antiviral therapy for at least five days, including hydroxychloroquine and / or favipiravir and patients who were followed-up for 30 days were included in this analysis. Results: We enrolled 1489 patients in this study. Overall, 775 (52%) patients were male and a mean age of patients was 38.9 ± 11.1 years. Of these patients, 537 of them were received favipiravir, 545 of them were received hydroxychloroquine and 407 of them were received both favipiravir and hydroxychloroquine. Symptoms improvement on the 14th day of follow-up was 1.8 times higher in the group of patients receiving hydroxychloroquine compared to patients who received favipiravir (p = 0.003). On the 3rd day of followup, PCR negativity rate was higher in patients who received hydroxychloroquine (p = 0.004). Hospitalization rates were similar in patients receiving favipiravir and hydroxychloroquine (p = 0.144). However, in the presence of pneumonia at the time of diagnosis, the hospitalization rate was 6.6 times higher in patients who received favipiravir than those who received hydroxychloroquine. Conclusion: The subgroups of patients treated with hydroxychloroquine and/or favipiravir did not have similar disease severities in our study. Therefore, further studies with homogeneous patient groups to be arranged prospectively are needed.Key words: COVID-19, hydroxychloroquine, favipiravir, outpatients, treatment

PDF

___

1. Dong X, Tian Z, Shen C, Zhao C. An overview of potential therapeutic agents to treat COVID-19. BioScience Trends 2020: 4; 14(5): 318-327. doi: 10.5582/bst.2020.03345
2. Xu J, Hussain S, Lu G, Zheng K, Wei S et al. Associations of Stay-at-Home Order and Face-Masking Recommendation with Trends in Daily New Cases and Deaths of LaboratoryConfirmed COVID-19 in the United States. Exploratory Research and Hypothesis in Medicine 2020: 1-10. doi: 10.14218/ERHM.2020.00045
3. Risch HA. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis. American Journal of Epidemiology 2020; 189(11): 1218-1226. doi: 10.1093/aje/ kwaa093
4. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine 2020; 383(21): 2030-2040. doi: 10.1056/ NEJMoa2022926
5. Yu B, Li C, Chen P, Zhou N, Wang L et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Science China Life Sciences 2020; 63(10): 1515-1521. doi: 10.1007/s11427-020-1732-2
6. Hong TS, Gonzalez J, Nahass RG, Brunetti L. Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. Pharmacy (Basel) 2020; 8(4): 208. doi: 10.3390/pharmacy8040208
7. Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. New Microbes and New Infections 2020; 38: 100776. doi: 10.1016/j.nmni.2020.100776
8. Chen Z, Hu J, Zhang Z, Jiang S, Han S et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv 2020.03.22.20040758. doi: 10.1101/2020.03.22.20040758
9. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology 2020; 16(3): 155-166. doi: 10.1038/s41584-020-0372-x
10. Liu J, Li S, Liu J, Liang B, Wang X et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020; 55: 102763. doi: 10.1016/j. ebiom.2020.102763
11. Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K et al. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of General Internal Medicine 2020; 35(11): 3308-3314. doi: 10.1007/s11606-020-06146-w
12. Lewis K, Chaudhuri D, Alshamsi F, Carayannopoulos L, Dearness K et al; GUIDE Group. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. PLoS One 2021; 16(1): e0244778. doi: 10.1371/journal.pone.0244778
13. Joshi S, Parkar J, Ansari A, Vora A, Talwar D et al. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases 2020; 102: 501-508. doi: 10.1016/j.ijid.2020.10.069
14. Shannon A, Selisko B, Le NT, Huchting J, Touret F et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nature Communications 2020; 11(1): 4682. doi: 10.1038/s41467-020-18463-z
15. Siordia JA Jr, Bernaba M, Yoshino K, Ulhaque A, Kumar S et al. Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. SN Comprehensive Clinical Medicine 2020: 1-12. doi: 10.1007/s42399-020-00399-6
16. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and metaanalysis. Virology Journal 2020; 17(1): 141. doi: 10.1186/ s12985-020-01412-z
17. Duvignaud A, Lhomme E, Pistone T, Onaisi R, Sitta R et al; COVERAGE study group. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Trials 2020; 21(1): 846. doi: 10.1186/s13063-020-04619-1
18. Hanna CR, Blyth KG, Burley G, Carmichael S, Evans C et al. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21(1): 935. doi: 10.1186/s13063-020-04891-1